[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369259-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369259-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","determinants-of-response-and-molecular-dynamics-in-her2er-breast-cancers-from-the-na-pher2-trial-receiving-her2-targeted-and-endocrine-therapies","Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies","","Improved outcomes in HER2+ female breast cancer have come from chemotherapy and anti-HER2 approaches, yet HER2+ER+ tumors show lower response rates. The phase 2 NA-PHER2 trial evaluated chemo-free preoperative HER2 blockade and CDK4/6 inhibition with or without endocrine therapy, and previously reported clinical endpoints. This study focuses on biomarker analyses using RNA sequencing and tumor-infiltrating lymphocyte assessment in serial biopsies, identifying predictors of pCR and Day14 Ki67 response and mapping treatment-induced molecular changes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/determinants-of-response-and-molecular-dynamics-in-her2er-breast-cancers-from-the-na-pher2-trial-receiving-her2-targeted-and-endocrine-therapies/369259/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/determinants-of-response-and-molecular-dynamics-in-her2er-breast-cancers-from-the-na-pher2-trial-receiving-her2-targeted-and-endocrine-therapies/369259.png","ImageObject",300,407,{"name":42,"@type":43},"Theodore","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of the biomarker analysis in the NA-PHER2 trial?","Question",{"text":63,"@type":64},"To identify biomarkers predictive of pathological complete response (pCR) or Day14 Ki67 response and to describe treatment-induced molecular changes using serial biopsy data.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were response groups defined in the study?",{"text":68,"@type":64},"By Ki67 stratification at Day14 and at surgery, forming three groups: Ki67 HighHigh, LowHigh, and LowLow.",{"name":70,"@type":61,"acceptedAnswer":71},"Which biological features were associated with pCR and Day14 Ki67 response?",{"text":72,"@type":64},"High immune infiltration and low ER signaling correlated with pCR, while TP53 mutations were associated with high Day14 Ki67.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369259,1790914093,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article [https://doi.org/10.1038/s41467-025-57293-9](https://doi.org/10.1038/s41467-025-57293-9)  \nDeterminants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies  \nReceived: 6 March 2024  \n\n| Accepted: 12 February 2025 |\n| --- |\n| |\n| Check for updates |\n\nMaurizio Callari 1, Matteo Dugo 2, Marco Barreca 1,3, Balázs Győrffy4,5,6, Barbara Galbardi2, Lucia Vigano 2, Alberta Locatelli 2, Chiara Dall’Ara 2, Marina Ferrarini2, Giancarlo Bisagni7, Marco Colleoni8, Mauro Mansutti9, Claudio Zamagni10, Lucia Del Mastro 11,12, Stefania Zambelli2,  \nAntonio Frassoldati13, Olivia Biasi8, Lajos Pusztai 14, Pinuccia Valagussa 1, Giuseppe Viale1,8, Luca Gianni1,16  & Giampaolo Bianchini 2,15,16   \nImproved outcomes in HER2+ female breast cancer have resulted from chemotherapy and anti-HER2 therapies. However, HER2+ER+ cancers exhibit lower response rates. The phase 2 NA-PHER2 trial (NCT02530424) investigated chemo-free preoperative HER2 blockade (trastuzumab + pertuzumab) and CDK4/6 inhibition (palbociclib) with or without endocrine therapy (fulvestrant) in HER2+ER+ breast cancer. Clinical endpoints (i.e. Ki67 dynamics and pathological complete response) were previously reported. Here we report on the biomarker analysis, secondary objective of the study. Through RNA sequencing and tumour inﬁltrating lymphocytes (TIL) assessment in serial biopsies, we identiﬁed biomarkers predictive of pCR or Day14 Ki67 response and unveiled treatment-induced molecular changes. High immune inﬁltration and low ER signalling correlated with pCR, while TP53 mutations associated with high Day14 Ki67. Stratiﬁcation based on Ki67 at Day14 and at surgery deﬁned three response groups (Ki67 HighHigh, LowHigh, LowLow), with divergent tumour and stroma expression dynamics. The HighHigh group showed dysfunctional immune inﬁltration and overexpression of therapeutic targets like PAK4 at baseline. The LowLow group exhibited a Luminal A phenotype by the end of treatment. This study expands our understanding of drivers and dynamics of HER2+ER+ tumour response, towards treatment tailoring.  \nThe prognosis ofHuman Epidermal Growth Factor Receptor-2positive (HER2 + ) breast cancers has improved substantially with the introduction of HER2-targeted neoadjuvant/adjuvant therapies1. The overall most effective regimens include multi-drug chemotherapy  \ncombined with dual HER2blockade. Among HER2+ cancers, large scale molecular and clinical differences remain between the estrogen receptor-positive (ER + ) and -negative (ER-) subgroups2. HER2+ER+ cancers have lower pathological complete response (pCR) rates to  \nA full list of afﬁliations appears at the end of the paper. e-mail: [luca.gianni@fondazionemichelangelo.org](luca.gianni@fondazionemichelangelo.org); [bianchini.giampaolo@hsr.it](bianchini.giampaolo@hsr.it)  \nneoadjuvant therapy than HER2+ER- tumours3–6. Therefore, they represent the highest proportion of HER2+ cancers that are candidate to adjuvant T-DM1 after neoadjuvant therapy, to which, however, they respond similarly to ER-tumours7.  \nER positivity only partially captures the variability in response to treatment; other aspects of tumour biology (e.g. proliferation) and its microenvironment (e.g. immune inﬁltration) have a relevant role8. Consequently, biomarker-guided alternative approaches that could improve patients’ outcome while reducing unnecessary toxicities are needed in the HER2+ER+ subgroup.  \nIn HER2+ER+ cancers, HER2 targeted therapies are additive/ synergistic with endocrine therapy, and response rates can be further improved with the addition of CDK4/6 inhibitors9,10. In the MonarchHER randomized Phase II trial, abemaciclib plus trastuzumab plus fulvestrant demonstrated improved progression free survival compared to chemotherapy plus trastuzumab in metastatic HER2+ER+ breast cancer11. In the two-cohorts NA-PHER2 Phase II neoadjuvant trial (NCT02530424) we tested the efﬁcacy of","cbCaip8ptDJ5qYqb","https://ap.wps.com/l/cbCaip8ptDJ5qYqb","pdf",4963254,15,"English","# Introduction\n## NA-PHER2 trial and clinical context\n# Methods\n## Serial biopsies, RNA sequencing, and TIL assessment\n# Results\n## Biomarker analysis and response groups based on Ki67","[{\"question\":\"What was the main aim of the biomarker analysis in the NA-PHER2 trial?\",\"answer\":\"To identify biomarkers predictive of pathological complete response (pCR) or Day14 Ki67 response and to describe treatment-induced molecular changes using serial biopsy data.\"},{\"question\":\"How were response groups defined in the study?\",\"answer\":\"By Ki67 stratification at Day14 and at surgery, forming three groups: Ki67 HighHigh, LowHigh, and LowLow.\"},{\"question\":\"Which biological features were associated with pCR and Day14 Ki67 response?\",\"answer\":\"High immune infiltration and low ER signaling correlated with pCR, while TP53 mutations were associated with high Day14 Ki67.\"}]","Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies | PDF",1790181640,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/718fd1a1fbe086758c4bd113fddec354.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7559310937cb1c761026063501247dde.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b3df085f973657c2dba4aba8b1dea0be.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a782a07c9dac70fc6cb1012aaa1ac954.webp",980,1301]